

Sabinsa News Release

MEDIA CONTACT: Suzanne Shelton | The Shelton Group
Suzanne@SheltonGroupPR.com | T: 847-676-4337

SABINSA GRANTED US PATENT ON LACTOSPORE® FOR IBS

East Windsor, NJ (March 15, 2017) – Sabinsa has been granted a US patent on the company’s shelf-stable probiotic LactoSpore® (*Bacillus coagulans* MTCC 5856) for its use for therapeutic management of Irritable Bowel Syndrome (IBS).

Patent No. US9579352 claims a method for managing the symptoms associated with IBS including abdominal pain, bloating or visible distension of abdomen, constipation and loose stools, by orally administering a formulation comprising *Bacillus coagulans* MTCC 5856 (not less than 2 billion spores) as a dietary supplement along with regular treatment. LactoSpore® ameliorates the symptoms of IBS as seen in a recently published human clinical trial (Majeed et al. Nutrition Journal (2016) 15:21 DOI 10.1186/s12937-016-0140-6). In the study, LactoSpore® demonstrated efficacy in relieving clinical symptoms in IBS patients.



In 2016 Health Canada, the federal department that regulates the products that help the Canadian people maintain and improve their health, issued a Product License to Sabinsa for a significant health claim on LactoSpore® Balance: “Helps relieve abdominal pain associated with IBS (Irritable Bowel Syndrome).”

“Sabinsa’s 136 patents demonstrate the continuous innovation process that Sabinsa proudly brings to its ingredients portfolio,” said Sabinsa Marketing Director Shaheen Majeed. “We deliver not only quality but efficacy as well, and this patent on LactoSpore delivers on that focus.”

About Sabinsa Corporation:



Sabinsa's mission is to provide alternative and complementary natural products for human nutrition and well-being. Over the past 28 years, Sabinsa has brought to market more than 100 standardized botanical extracts, and privately funded clinical studies in conjunction with prestigious institutions in support of these products. With more than 100 full-time scientists conducting ongoing research in India and the United States, Sabinsa and parent company Sami Labs Ltd. continue to develop, patent and manufacture phytonutrients for the world market, with ingredients that are both Halal and Kosher. For more information, visit www.sabinsa.com.

-- END --